nach oben

Erschienen in:

02.03.2023 | Original Article

Comparison of PD-L1 and VISTA expression status in primary and recurrent/refractory tissue after (chemo)radiotherapy in head and neck cancer

verfasst von: Görkem Yazıcı Şener, Osman Sütcüoğlu, MD, Betül Öğüt, Deniz Can Güven, Altan Kavuncuoğlu, Nuriye Özdemir, Ahmet Özet, Sercan Aksoy, Yeşim Gaye Güler Tezel, Nalan Akyürek, Ozan Yazıcı

Erschienen in: Strahlentherapie und Onkologie | Ausgabe 8/2023

Einloggen, um Zugang zu erhalten

Abstract

Background

PD-L1 and VISTA are thought to play a role in escape from the immune system, tumor progression, and treatment response in tumoral tissue. The current study aimed to evaluate the effects of radiotherapy (RT) and chemoradiotherapy (CRT) on PD-L1 and VISTA expression in head and neck cancers.

Methods

PD-L1 and VISTA expression were compared between the primary biopsy taken at the time of diagnosis and refractory tissue biopsies of patients who received definitive CRT or recurrent tissue biopsies of patients who had surgery followed by adjuvant RT or CRT.

Results

In total, 47 patients were included. Radiotherapy had no effect on the expression levels of PD-L1 and VISTA in patients with head and neck cancer (p = 0.542 and p = 0.425, respectively). A positive correlation was found between PD-L1 and VISTA expression (p < 0.001; r = 0.560). PD-L1 and VISTA expression in the first biopsy were found to be significantly higher in clinical lymph node-positive patients compared to node-negative patients (PD-L1 p = 0.038; VISTA p = 0.018). The median overall survival of patients with ≥ 1% VISTA expression in the initial biopsy was significantly shorter than that of patients with < 1% VISTA expression (52.4 vs. 110.1 months, respectively; p = 0.048).

Conclusion

It was found that PD-L1 and VISTA expression did not change with RT or CRT. Further studies are needed to evaluate the relationship of PD-L1 and VISTA expression with RT and CRT.

Nur mit Berechtigung zugänglich

Siegel RL, Miller KD, Fuchs HE, Jemal A (2021) Cancer statistics, 2021. CA Cancer J Clin 71(1):7–33. https://doi.org/10.3322/caac.21654CrossRefPubMed

Cohen EEW, Bell RB, Bifulco CB, Burtness B, Gillison ML, Harrington KJ et al (2019) The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC). J Immunother Cancer 7(1):184. https://doi.org/10.1186/s40425-019-0662-5CrossRefPubMedCentralPubMed

Cognetti DM, Weber RS, Lai SY (2008) Head and neck cancer: an evolving treatment paradigm. Cancer 113(7):1911–1932. https://doi.org/10.1002/cncr.23654CrossRefPubMed

Havel JJ, Chowell D, Chan TA (2019) The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy. Nat Rev Cancer 19(3):133–150. https://doi.org/10.1038/s41568-019-0116-xCrossRefPubMedCentralPubMed

Gibney GT, Weiner LM, Atkins MB (2016) Predictive biomarkers for checkpoint inhibitor-based immunotherapy. Lancet Oncol 17(12):e542–e51. https://doi.org/10.1016/s1470-2045(16)30406-5CrossRefPubMedCentralPubMed

Maleki Vareki S, Garrigós C, Duran I (2017) Biomarkers of response to PD-1/PD-L1 inhibition. Crit Rev Oncol Hematol 116:116–124. https://doi.org/10.1016/j.critrevonc.2017.06.001CrossRefPubMed

Cramer JD, Burtness B, Ferris RL (2019) Immunotherapy for head and neck cancer: recent advances and future directions. Oral Oncol 99:104460. https://doi.org/10.1016/j.oraloncology.2019.104460CrossRefPubMedCentralPubMed

Nowak EC, Lines JL, Varn FS, Deng J, Sarde A, Mabaera R et al (2017) Immunoregulatory functions of VISTA. Immunol Rev 276(1):66–79. https://doi.org/10.1111/imr.12525CrossRefPubMedCentralPubMed

Zou W, Chen L (2008) Inhibitory B7-family molecules in the tumour microenvironment. Nat Rev Immunol 8(6):467–477. https://doi.org/10.1038/nri2326CrossRefPubMed

10.

Tagliamento M, Bironzo P, Novello S (2020) New emerging targets in cancer immunotherapy: the role of VISTA. ESMO Open 4(3):e683. https://doi.org/10.1136/esmoopen-2020-000683CrossRefPubMedCentralPubMed

11.

Huang X, Zhang X, Li E, Zhang G, Wang X, Tang T et al (2020) VISTA: an immune regulatory protein checking tumor and immune cells in cancer immunotherapy. J Hematol Oncol 13(1):83. https://doi.org/10.1186/s13045-020-00917-yCrossRefPubMedCentralPubMed

12.

Zhu AX, Finn RS, Ikeda M, Sung MW, Baron AD, Kudo M et al (2020) A phase Ib study of lenvatinib (LEN) plus pembrolizumab (PEMBRO) in unresectable hepatocellular carcinoma (uHCC). American Society of Clinical OncologyCrossRef

13.

Makowska A, Meier S, Shen L, Busson P, Baloche V, Kontny U (2021) Anti-PD‑1 antibody increases NK cell cytotoxicity towards nasopharyngeal carcinoma cells in the context of chemotherapy-induced upregulation of PD‑1 and PD-L1. Cancer Immunol Immunother 70(2):323–336. https://doi.org/10.1007/s00262-020-02681-xCrossRefPubMed

14.

Tran L, Allen CT, Xiao R, Moore E, Davis R, Park SJ et al (2017) Cisplatin alters antitumor immunity and synergizes with PD-1/PD-L1 inhibition in head and neck squamous cell carcinoma. Cancer Immunol Res 5(12):1141–1151. https://doi.org/10.1158/2326-6066.Cir-17-0235CrossRefPubMedCentralPubMed

15.

Demaria S, Golden EB, Formenti SC (2015) Role of local radiation therapy in cancer immunotherapy. JAMA Oncol 1(9):1325–1332. https://doi.org/10.1001/jamaoncol.2015.2756CrossRefPubMed

16.

Dewan MZ, Galloway AE, Kawashima N, Dewyngaert JK, Babb JS, Formenti SC et al (2009) Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA‑4 antibody. Clin Cancer Res 15(17):5379–5388. https://doi.org/10.1158/1078-0432.Ccr-09-0265CrossRefPubMedCentralPubMed

17.

Buchwald ZS, Wynne J, Nasti TH, Zhu S, Mourad WF, Yan W et al (2018) Radiation, immune checkpoint blockade and the abscopal effect: a critical review on timing, dose and fractionation. Front Oncol 8:612. https://doi.org/10.3389/fonc.2018.00612CrossRefPubMedCentralPubMed

18.

Ferris RL, Blumenschein G, Fayette J, Guigay J, Colevas AD, Licitra L et al (2016) Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med 375(19):1856–1867. https://doi.org/10.1056/NEJMoa1602252CrossRefPubMedCentralPubMed

19.

Cohen EEW, Soulières D, Le Tourneau C, Dinis J, Licitra L, Ahn MJ et al (2019) Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study. Lancet 393(10167):156–167. https://doi.org/10.1016/s0140-6736(18)31999-8CrossRefPubMed

20.

Bahleda R, Braiteh F, Balmanoukian A, Braña I, Hodi F, Garbo L et al (2017) Long-term safety and clinical outcomes of atezolizumab in head and neck cancer: phase Ia trial results. Ann Oncol 28:v373CrossRef

21.

Katsuya Y, Horinouchi H, Asao T, Kitahara S, Goto Y, Kanda S et al (2016) Expression of programmed death 1 (PD-1) and its ligand (PD-L1) in thymic epithelial tumors: Impact on treatment efficacy and alteration in expression after chemotherapy. Lung Cancer 99:4–10. https://doi.org/10.1016/j.lungcan.2016.05.007CrossRefPubMed

22.

Pilones KA, Hensler M, Daviaud C, Kraynak J, Fucikova J, Galluzzi L et al (2020) Converging focal radiation and immunotherapy in a preclinical model of triple negative breast cancer: contribution of VISTA blockade. OncoImmunology 9(1):1830524. https://doi.org/10.1080/2162402x.2020.1830524CrossRefPubMedCentralPubMed

23.

van den Ende T, van den Boorn HG, Hoonhout NM, van Etten-Jamaludin FS, Meijer SL, Derks S et al (2020) Priming the tumor immune microenvironment with chemo(radio)therapy: a systematic review across tumor types. Biochim Biophys Acta Rev Cancer 1874(1):188386. https://doi.org/10.1016/j.bbcan.2020.188386CrossRefPubMed

24.

Gong J, Le TQ, Massarelli E, Hendifar AE, Tuli R (2018) Radiation therapy and PD-1/PD-L1 blockade: the clinical development of an evolving anticancer combination. J Immunother Cancer 6(1):46. https://doi.org/10.1186/s40425-018-0361-7CrossRefPubMedCentralPubMed

25.

Wang Y, Kim TH, Fouladdel S, Zhang Z, Soni P, Qin A et al (2019) PD-L1 expression in circulating tumor cells increases during radio(chemo)therapy and indicates poor prognosis in non-small cell lung cancer. Sci Rep 9(1):566. https://doi.org/10.1038/s41598-018-36096-7CrossRefPubMedCentralPubMed

26.

Oweida A, Lennon S, Calame D, Korpela S, Bhatia S, Sharma J et al (2017) Ionizing radiation sensitizes tumors to PD-L1 immune checkpoint blockade in orthotopic murine head and neck squamous cell carcinoma. OncoImmunology 6(10):e1356153. https://doi.org/10.1080/2162402x.2017.1356153CrossRefPubMedCentralPubMed

27.

Hecht M, Büttner-Herold M, Erlenbach-Wünsch K, Haderlein M, Croner R, Grützmann R et al (2016) PD-L1 is upregulated by radiochemotherapy in rectal adenocarcinoma patients and associated with a favourable prognosis. Eur J Cancer 65:52–60. https://doi.org/10.1016/j.ejca .2016.06.015CrossRefPubMed

28.

Patel KR, Martinez A, Stahl JM, Logan SJ, Perricone AJ, Ferris MJ et al (2018) Increase in PD-L1 expression after pre-operative radiotherapy for soft tissue sarcoma. OncoImmunology 7(7):e1442168CrossRefPubMedCentralPubMed

29.

Yoneda K, Kuwata T, Kanayama M, Mori M, Kawanami T, Yatera K et al (2019) Alteration in tumoural PD-L1 expression and stromal CD8-positive tumour-infiltrating lymphocytes after concurrent chemo-radiotherapy for non-small cell lung cancer. Br J Cancer 121(6):490–496. https://doi.org/10.1038/s41416-019-0541-3CrossRefPubMedCentralPubMed

30.

Qian JM, Schoenfeld JD (2020) Radiotherapy and immunotherapy for head and neck cancer: current evidence and challenges. Front Oncol 10:608772. https://doi.org/10.3389/fonc.2020.608772CrossRefPubMed

31.

Schoop H, Bregenzer A, Halske C, Behrens HM, Krüger S, Egberts JH et al (2020) Therapy resistance in neoadjuvantly treated gastric cancer and cancer of the gastroesophageal junction is associated with an increased expression of immune checkpoint inhibitors-comparison against a therapy naïve cohort. Transl Oncol 13(2):165–176. https://doi.org/10.1016/j.tranon.2019.11.004CrossRefPubMed

32.

McBride S, Sherman E, Tsai CJ, Baxi S, Aghalar J, Eng J et al (2021) Randomized phase II trial of nivolumab with stereotactic body radiotherapy versus nivolumab alone in metastatic head and neck squamous cell carcinoma. J Clin Oncol 39(1):30–37. https://doi.org/10.1200/jco.20.00290CrossRefPubMed

33.

Theelen W, Peulen HMU, Lalezari F, van der Noort V, de Vries JF, Aerts J et al (2019) Effect of pembrolizumab after stereotactic body radiotherapy vs pembrolizumab alone on tumor response in patients with advanced non-small cell lung cancer: results of the PEMBRO-RT phase 2 randomized clinical trial. JAMA Oncol 5(9):1276–1282. https://doi.org/10.1001/jamaoncol.2019.1478CrossRefPubMedCentralPubMed

34.

Patel SP, Kurzrock R (2015) PD-L1 expression as a predictive biomarker in cancer immunotherapy. Mol Cancer Ther 14(4):847–856. https://doi.org/10.1158/1535-7163.Mct-14-0983CrossRefPubMed

35.

Downes MR, Slodkowska E, Katabi N, Jungbluth AA, Xu B (2020) Inter- and intraobserver agreement of programmed death ligand 1 scoring in head and neck squamous cell carcinoma, urothelial carcinoma and breast carcinoma. Histopathology 76(2):191–200. https://doi.org/10.1111/his.13946CrossRefPubMed

36.

Rasmussen JH, Lelkaitis G, Håkansson K, Vogelius IR, Johannesen HH, Fischer BM et al (2019) Intratumor heterogeneity of PD-L1 expression in head and neck squamous cell carcinoma. Br J Cancer 120(10):1003–1006. https://doi.org/10.1038/s41416-019-0449-yCrossRefPubMedCentralPubMed

37.

Burtness B, Harrington KJ, Greil R, Soulières D, Tahara M, de Castro G Jr. et al (2019) Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet 394(10212):1915–1928. https://doi.org/10.1016/s0140-6736(19)32591-7CrossRefPubMed

38.

Liu J, Yuan Y, Chen W, Putra J, Suriawinata AA, Schenk AD et al (2015) Immune-checkpoint proteins VISTA and PD‑1 nonredundantly regulate murine T‑cell responses. Proc Natl Acad Sci U S A 112(21):6682–6687. https://doi.org/10.1073/pnas.1420370112CrossRefPubMedCentralPubMed

39.

Kakavand H, Jackett LA, Menzies AM, Gide TN, Carlino MS, Saw RPM et al (2017) Negative immune checkpoint regulation by VISTA: a mechanism of acquired resistance to anti-PD‑1 therapy in metastatic melanoma patients. Mod Pathol 30(12):1666–1676. https://doi.org/10.1038/modpathol.2017.89CrossRefPubMed

40.

Wu L, Deng WW, Huang CF, Bu LL, Yu GT, Mao L et al (2017) Expression of VISTA correlated with immunosuppression and synergized with CD8 to predict survival in human oral squamous cell carcinoma. Cancer Immunol Immunother 66(5):627–636. https://doi.org/10.1007/s00262-017-1968-0CrossRefPubMed

41.

Zhang M, Pang H‑J, Zhao W, Li Y‑F, Yan L‑X, Dong Z‑Y et al (2018) VISTA expression associated with CD8 confers a favorable immune microenvironment and better overall survival in hepatocellular carcinoma. BMC Cancer 18(1):1–8

42.

Zong L, Zhou Y, Zhang M, Chen J, Xiang Y (2020) VISTA expression is associated with a favorable prognosis in patients with high-grade serous ovarian cancer. Cancer Immunol Immunother 69(1):33–42. https://doi.org/10.1007/s00262-019-02434-5CrossRefPubMed

43.

Cao X, Ren X, Zhou Y, Mao F, Lin Y, Wu H et al (2020) VISTA expression on immune cells correlates with favorable prognosis in patients with triple-negative breast cancer. Front Oncol 10:583966. https://doi.org/10.3389/fonc.2020.583966CrossRefPubMed

44.

Vassilakopoulou M, Avgeris M, Velcheti V, Kotoula V, Rampias T, Chatzopoulos K et al (2016) Evaluation of PD-L1 expression and associated tumor-infiltrating lymphocytes in laryngeal squamous cell carcinoma. Clin Cancer Res 22(3):704–713. https://doi.org/10.1158/1078-0432.Ccr-15-1543CrossRefPubMed

45.

Lin YM, Sung WW, Hsieh MJ, Tsai SC, Lai HW, Yang SM et al (2015) High PD-L1 expression correlates with metastasis and poor prognosis in oral squamous cell carcinoma. PLoS ONE 10(11):e142656. https://doi.org/10.1371/journal.pone.0142656CrossRefPubMedCentralPubMed

46.

Liao H, Zhu H, Liu S, Wang H (2018) Expression of V‑domain immunoglobulin suppressor of T cell activation is associated with the advanced stage and presence of lymph node metastasis in ovarian cancer. Oncol Lett 16(3):3465–3472. https://doi.org/10.3892/ol.2018.9059CrossRefPubMedCentralPubMed

47.

Yang WF, Wong MCM, Thomson PJ, Li KY, Su YX (2018) The prognostic role of PD-L1 expression for survival in head and neck squamous cell carcinoma: a systematic review and meta-analysis. Oral Oncol 86:81–90. https://doi.org/10.1016/j.oraloncology.2018.09.016CrossRefPubMed

48.

Tang H, Zhou X, Ye Y, Zhou Y, Wu C, Xu Y (2020) The different role of PD-L1 in head and neck squamous cell carcinomas: a meta-analysis. Pathol Res Pract 216(1):152768. https://doi.org/10.1016/j.prp.2019.152768CrossRefPubMed

49.

Bauml J, Seiwert TY, Pfister DG, Worden F, Liu SV, Gilbert J et al (2017) Pembrolizumab for platinum- and cetuximab-refractory head and neck cancer: results from a single-arm, phase II study. J Clin Oncol 35(14):1542–1549. https://doi.org/10.1200/jco.2016.70.1524CrossRefPubMedCentralPubMed

50.

Ferris RL, Blumenschein G Jr., Fayette J, Guigay J, Colevas AD, Licitra L et al (2016) Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med 375(19):1856–1867. https://doi.org/10.1056/NEJMoa1602252CrossRefPubMedCentralPubMed

51.

Mehra R, Seiwert TY, Gupta S, Weiss J, Gluck I, Eder JP et al (2018) Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012. Br J Cancer 119(2):153–159. https://doi.org/10.1038/s41416-018-0131-9CrossRefPubMedCentralPubMed

52.

Aydil U, Akmansu M, Gümüşay Ö, Eravcı FC, Bakkal FK, Yazıcı Ö et al (2019) Failure of concurrent chemoradiotherapy for organ preservation in laryngeal cancer: survival outcomes and recurrence patterns. Ear Nose Throat J 98(7):E92–e6. https://doi.org/10.1177/0145561319839788CrossRefPubMed

53.

Agra IM, Ferlito A, Takes RP, Silver CE, Olsen KD, Stoeckli SJ et al (2012) Diagnosis and treatment of recurrent laryngeal cancer following initial nonsurgical therapy. Head Neck 34(5):727–735. https://doi.org/10.1002/hed.21739CrossRefPubMed

54.

Esteller E, Vega MC, López M, Quer M, León X (2011) Salvage surgery after locoregional failure in head and neck carcinoma patients treated with chemoradiotherapy. Eur Arch Otorhinolaryngol 268(2):295–301. https://doi.org/10.1007/s00405-010-1365-1CrossRefPubMed

55.

León X, Quer M, Orús C, López M, Gras JR, Vega M (2001) Results of salvage surgery for local or regional recurrence after larynx preservation with induction chemotherapy and radiotherapy. Head Neck 23(9):733–738. https://doi.org/10.1002/hed.1104CrossRefPubMed

56.

Birkeland AC, Beesley L, Bellile E, Rosko AJ, Hoesli R, Chinn SB et al (2017) Predictors of survival after total laryngectomy for recurrent/persistent laryngeal squamous cell carcinoma. Head Neck 39(12):2512–2518. https://doi.org/10.1002/hed.24918CrossRefPubMedCentralPubMed

Titel: Comparison of PD-L1 and VISTA expression status in primary and recurrent/refractory tissue after (chemo)radiotherapy in head and neck cancer
verfasst von: Görkem Yazıcı Şener
Osman Sütcüoğlu, MD
Betül Öğüt
Deniz Can Güven
Altan Kavuncuoğlu
Nuriye Özdemir
Ahmet Özet
Sercan Aksoy
Yeşim Gaye Güler Tezel
Nalan Akyürek
Ozan Yazıcı
Publikationsdatum: 02.03.2023
Verlag: Springer Berlin Heidelberg
Erschienen in: Strahlentherapie und Onkologie / Ausgabe 8/2023
Print ISSN: 0179-7158
Elektronische ISSN: 1439-099X
DOI: https://doi.org/10.1007/s00066-023-02053-1

Springer Medizin

Comparison of PD-L1 and VISTA expression status in primary and recurrent/refractory tissue after (chemo)radiotherapy in head and neck cancer